Danielle Ulanet

1.6k citations

23 papers · 1.2k indexed · h-index 12

Impact in

Physiology top 5%
Immunology top 10%
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses

Papers in

Cancer Research 8
- Cancer Genomics and Diagnostics 5
- Cancer, Hypoxia, and Metabolism 3
Molecular Biology 17
- DNA Repair Mechanisms 6
- Biochemical and Molecular Research 3
- RNA modifications and cancer 3
- Epigenetics and DNA Methylation 2

Co-authors: Antony Rosen Livia Casciola‐Rosen Felipe Andrade Douglas Hanahan Dale L. Ludwig C. Ronald Kahn Jesper Nylandsted Thomas Kirkegaard
Journals: PLoS ONE (3 papers)Blood (2 papers)npj Precision Oncology (2 papers)Proceedings of the National Academy of Sciences (2 papers)Cancer Research (2 papers)
Partner nations: United States Denmark United Kingdom

In The Last Decade

Danielle Ulanet

21 papers receiving 1.2k citations

Peers

Countries citing papers authored by Danielle Ulanet

Since Specialization

Citations

This map shows the geographic impact of Danielle Ulanet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danielle Ulanet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danielle Ulanet more than expected).

Fields of papers citing papers by Danielle Ulanet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danielle Ulanet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danielle Ulanet. The network helps show where Danielle Ulanet may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Danielle Ulanet, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Danielle Ulanet Line = papers co-authored together Danielle Ulanet links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanoma npj Precision Oncology ·Natalie Y.L. Ngoi, Ian M. Silverman, Adrienne Johnson, Alves Tiago Rafael, Joseph D. Schonhoft, Michal Zimmermann, Danielle Ulanet, Hye‐Yeon Kim, (unknown), Carolina Salguero, Marcelo Henrique Procópio Pelegrino, Jordi Rodón, Victoria Rimkunas, María Koehler, Timothy A. Yap	2025	1
2	Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study) JNCI Journal of the National Cancer Institute ·Elisa Fontana, Ezra Y. Rosen, Elizabeth K. Lee, Martin Højgaard, Niharika B. Mettu, Stéphanie Lheureux, Benedito A. Carneiro, Gregory M. Coté, Louise Carter, Ruth Plummer, Devalingam Mahalingam, Adrian J. Fretland, Joseph D. Schonhoft, Ian M. Silverman, Marisa J. Wainszelbaum, Yi Xu, Danielle Ulanet, María Koehler, Timothy A. Yap	2024	7
3	Post-therapy emergence of an NBN reversion mutation in a patient with pancreatic acinar cell carcinoma npj Precision Oncology ·Soroka Baker, Ian M. Silverman, Joseph D. Schonhoft, Adrienne Johnson, Pier Selenica, Danielle Ulanet, Victoria Rimkunas, Jorge S. Reis‐Filho	2024	1
4	Abstract B001: Identification of monoallelic ATM loss-of-function and homologous recombination deficiency (HRD) in high-grade ovarian tumor with prolonged response to camonsertib and low-dose gemcitabine combination therapy Cancer Research ·Stéphanie Lheureux, Joseph D. Schonhoft, Ian M. Silverman, Julia Yang, Adrienne Johnson, Hongjiang Wang, Denise Juaçaba Cavalcante, Trevor J. Pugh, Parham Nejad, Bernard Lam, Eric Vanaken, Ashley Adile, Stephenie D. Prokopec, Jeffrey P. Bruce, Danielle Ulanet, María Koehler, Ezra Y. Rosen, Victoria Rimkunas	2024	0
5	Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib Clinical Cancer Research ·Ezra Y. Rosen, Timothy A. Yap, Elizabeth K. Lee, Martin Højgaard, Niharika B. Mettu, Stéphanie Lheureux, Benedito A. Carneiro, Ruth Plummer, Adrian J. Fretland, Danielle Ulanet, Alex Primavesi, Robin McDougall, María Koehler, Elisa Fontana	2023	4
6	80. Identification of a post-platinum NBN reversion in a pancreatic cancer patient with a co-occurring NTRK1 fusion Cancer Genetics ·Adrienne Johnson, Pier Selenica, Joseph D. Schonhoft, Danielle Ulanet, Victoria Rimkunas, Jorge S. Reis‐Filho, Ian M. Silverman, Meredith Pelster	2023	0
7	Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia EMBO Molecular Medicine ·Joan So, Alexander C. Lewis, Lorey Smith, Kym L. Stanley, Chisom Jude Okeke, Márcio João, Lizzy Pijpers, Pilar M. Domínguez, Simon J. Hogg, Stephin J. Vervoort, Fiona C. Brown, Ricky W. Johnstone, Т.Т. Абдукадырова, Danielle Ulanet, L. Adornis Vernalis, F. L. MacPhail, Lev M. Kats	2022	17
8	Abstract CT030: Genomic and pathologic determinants of response to RP-3500, an ataxia telangiectasia and Rad3-related inhibitor (ATRi), in patients (pts) with DNA damage repair (DDR) loss-of-function (LOF) mutant tumors in the Phase 1/2 TRESR trial Cancer Research ·Timothy A. Yap, Ian M. Silverman, Elisa Fontana, Elizabeth Lee, David R. Spigel, Martin Højgaard, Stéphanie Lheureux, Niharika B. Mettu, Benedito A. Carneiro, Louise Carter, Dietlind Zuehlke, Joseph D. Schonhoft, Danielle Ulanet, Parham Nejad, Peter Manley, Jorge S. Reis‐Filho, Yi Xu, Victoria Rimkunas, María Koehler, Ezra Y. Rosen	2022	8
9	Abstract CC04-01: First-in-human biomarker-driven phase I TRESR trial of ataxia telangiectasia and Rad3-related inhibitor (ATRi) RP-3500 in patients (pts) with advanced solid tumors harboring synthetic lethal (SL) genomic alterations Molecular Cancer Therapeutics ·Timothy A. Yap, Elizabeth Lee, David R. Spigel, Elisa Fontana, Martin Højgaard, Stéphanie Lheureux, Niharika B. Mettu, Louise Carter, Ruth Plummer, Danielle Ulanet, Peter Manley, Walter C. Liebold, Ezra Y. Rosen	2021	4
10	Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and in Vivo Blood ·Zhihong Zeng, Natalia Baran, Sergej Konoplev, Antonio Cavazos, Qi Zhang, Vinitha M. Kuruvilla, Philip L. Lorenzi, Hagop M. Kantarjian, Michael Andreeff, Courtney D. DiNardo, Joshua Murtie, Danielle Ulanet, Marina Konopleva	2019	2
11	Differential Aspartate Usage Identifies a Subset of Cancer Cells Particularly Dependent on OGDH Cell Reports ·Eric L. Allen, Danielle Ulanet, David Pirman, Christopher E. Mahoney, X Chen, Yaguang Si, 修一金子, Lingling Huang, A. C. Smith, Sung Choe, Michelle Clasquin, Erin Artin, Zi Peng Fan, Giovanni Cianchetta, Joshua Murtie, Marion Dorsch, Shengfang Jin, Gromoslaw A. Smolen	2016	53
12	Mesenchymal Phenotype Predisposes Lung Cancer Cells to Impaired Proliferation and Redox Stress in Response to Glutaminase Inhibition PLoS ONE ·Danielle Ulanet, رحاب الدسوقی السید الغماز, Abhishek Jha, Sung Choe, Ying Wang, Buvaneshwari Muthirayan, Mya Steadman, Byron DeLaBarre, Stefan Größ, Edward M. Driggers, Marion Dorsch, Jonathan Hurov	2014	39
13	Mesenchymal phenotype predisposes lung cancer cells to impaired proliferation and redox stress in response to glutaminase inhibition Cancer & Metabolism ·Danielle Ulanet, Abhishek Jha, رحاب الدسوقی السید الغماز, Sung Choe, Andréa Regina Lopes Cunha, Buvaneshwari Muthirayan, Mya Steadman, Byron DeLaBarre, Stefan Größ, Edward M. Driggers, Marion Dorsch, Jonathan Hurov	2014	21
14	Transformation-Associated Changes in Sphingolipid Metabolism Sensitize Cells to Lysosomal Cell Death Induced by Inhibitors of Acid Sphingomyelinase Cancer Cell ·Nikolaj H.T. Petersen, Ole Dines Olsen, Line Groth‐Pedersen, A. G�ntherschulze, Mesut Bilgin, Susanne Redmer, Marie S. Ostenfeld, Danielle Ulanet, Tobias H. Dovmark, Nisenbaum Karin, Signe Diness Vindeløv, Douglas Hanahan, Christoph Arenz, Christer S. Ejsing, Thomas Kirkegaard, Mikkel Rohde, Jesper Nylandsted, Marja Jäättelä	2013	278
15	Loss of p19Arf Facilitates the Angiogenic Switch and Tumor Initiation in a Multi-Stage Cancer Model via p53-Dependent and Independent Mechanisms PLoS ONE ·Danielle Ulanet, Douglas Hanahan	2010	16
16	Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy Proceedings of the National Academy of Sciences ·Danielle Ulanet, Dale L. Ludwig, C. Ronald Kahn, Douglas Hanahan	2010	193
17	Genetic Ablation of Bcl-x Attenuates Invasiveness without Affecting Apoptosis or Tumor Growth in a Mouse Model of Pancreatic Neuroendocrine Cancer PLoS ONE ·Jeffrey H. Hager, Danielle Ulanet, Lothar Hennighausen, Douglas Hanahan	2009	16
18	Selective cleavage of nucleolar autoantigen B23 by granzyme B in differentiated vascular smooth muscle cells: Insights into the association of specific autoantibodies with distinct disease phenotypes Arthritis & Rheumatism ·Danielle Ulanet, Nicholas A. Flavahan, Livia Casciola‐Rosen, Antony Rosen	2004	29
19	Autoantibodies against B23, a nucleolar phosphoprotein, occur in scleroderma and are associated with pulmonary hypertension Arthritis Care & Research ·Danielle Ulanet, Fredrick M. Wigley, Allan C. Gelber, Antony Rosen	2003	51
20	Cleavage by Granzyme B Is Strongly Predictive of Autoantigen Status The Journal of Experimental Medicine ·Livia Casciola‐Rosen, Felipe Andrade, Danielle Ulanet, W. Urbańska, Antony Rosen	1999	397

About Danielle Ulanet

Danielle Ulanet is a scholar working on Cancer Research, Molecular Biology, Pathology and Forensic Medicine, Oncology and Immunology, having authored 23 papers that have together received 1.2k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (6 papers), Cancer Genomics and Diagnostics (5 papers), Cancer, Hypoxia, and Metabolism (3 papers), Biochemical and Molecular Research (3 papers), RNA modifications and cancer (3 papers), PARP inhibition in cancer therapy (3 papers), Neuroendocrine Tumor Research Advances (2 papers) and Epigenetics and DNA Methylation (2 papers). The work is most often cited by research in Physiology (82 citations), Immunology (342 citations), Cancer Research (182 citations), Rheumatology (148 citations) and Molecular Biology (647 citations). Danielle Ulanet has collaborated with scholars based in United States, Denmark and United Kingdom. Frequent co-authors include Antony Rosen, Livia Casciola‐Rosen, Felipe Andrade, Douglas Hanahan, Dale L. Ludwig, C. Ronald Kahn, Jesper Nylandsted, Thomas Kirkegaard, Marie S. Ostenfeld and Tobias H. Dovmark. Their work appears in journals such as PLoS ONE, Blood, npj Precision Oncology, Proceedings of the National Academy of Sciences and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact